Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab

By sjmartinez • August 30, 2024

Shen YC, Liu TH, Nicholas A, Soyama A, Yuan CT, Chen TC, Eguchi S, Yoshizumi T, Itoh S, Nakamura N, Kosaka H, Kaibori M, Ishii T, Hatano E, Ogawa C, Naganuma A, Kakizaki S, Cheng CH, Lin PT, Su YY, Chuang CH, Lu LC, Wu CJ, Wang HW, Rau KM, Hsu CH, Lin SM, Huang YH, Hernandez S, Finn RS, Kudo M, Cheng AL. Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab. J Clin Oncol. 2024 Aug 28:JCO2400645. doi: 10.1200/JCO.24.00645. Epub ahead of print. PMID: 39197119.

Tags: Hematology/Oncology, Publications

Cell free RNA detection of pancreatic cancer in pre diagnostic high risk and symptomatic patients

Moore TW, Spiliotopoulos E, Callahan RL, Kirschbaum CW, Bailey CF, Kim HJ, Roskams-Hieter B, Goncalves F, Keith D, Grossberg AJ, Spellman PT, Mills GB, Sears[...]

US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan

Rugo H, Bardia A, Bruno DS, Ernani V, Hamilton E, Heist R, Jhaveri K, Levy B, Lisberg A, O'Shaughnessy J, Sands J, Spira A, Tolaney[...]

Melisi D, Macarulla T, De La Fouchardière C, Pazo Cid RA, Chandana SR, Kiss I, Lee WJ, Goetze TO, Van Cutsem E, Paulson AS, Bekaii-Saab[...]